SABS

SAB BiotherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The bullish view still rests on SAB-142: management said in the March 9, 2026 release that SAFEGUARD is underway, multiple patients had been dosed, enrollment was on track for end-2026 completion, and the company had operational runway through 2028, which can support continued de-risking if the next update confirms execution [#PR-2026-03-09].

Posture

Defensive

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta +5.4.

What can break

Clinical execution risk remains high because the core thesis depends on timely SAFEGUARD enrollment and later topline data, with limited diversification beyond SAB-142 [#PR-2026-03-09] [#10-K-2026-03-09].

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $3.75 · Bull $9.38 · Bear $2.25

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-09 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net —

Target $11.33

Why

Momentum28 · Δ7d +2.8

Value44 · Δ7d -0.0

Sentiment71 · Δ7d +5.4

So what

Weak posture. Prioritize risk control and patience.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Sentiment · See AI snapshot

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+2.8

Δ21d

+4.9

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.0

Δ21d

+0.4

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+5.4

Δ21d

+7.4

Why this grade

Composite grade D. Momentum 28.4 / Value 43.8 / Sentiment 70.5

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$270.68M

Beta

0.59

Shares Out

76.46M

P/E (TTM) · Derived

16.0

P/S (TTM)

1552.31

P/FCF (TTM) · Derived

-2.22

Rev YoY

-100.0%

EPS YoY

-37.0%

Gross Margin

-2647.6%

Op Margin

-37656.5%

Net Debt

-$90.64M

Current Ratio

11.45

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology